Early Use of Gp IIb–IIIa Inhibitors in Heart Attack Treatment
Author Information
Author(s): De Luca G, Gibson C M, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz H-R, Zorman S, Gabriel H M, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van’t Hof A W J
Primary Institution: Eastern Piedmont University, Novara, Italy
Hypothesis
The study aims to evaluate the benefits of early administration of Gp IIb–IIIa inhibitors in patients undergoing primary angioplasty for STEMI.
Conclusion
Early administration of Gp IIb–IIIa inhibitors improves preprocedural recanalisation and ST-segment resolution, with non-significant mortality benefits except for abciximab.
Supporting Evidence
- Early Gp IIb–IIIa inhibitors improved preprocedural TIMI 3 flow.
- Complete ST-segment resolution was significantly higher with early Gp IIb–IIIa inhibitors.
- Mortality benefits were observed with early abciximab compared to late administration.
Takeaway
Giving certain heart medications early can help patients feel better faster and may help them live longer, especially if they get a specific drug called abciximab.
Methodology
The study combined individual patient data from 11 randomized trials on early versus late administration of Gp IIb–IIIa inhibitors in STEMI patients.
Potential Biases
The trials included were highly selected, which may not represent the general population of STEMI patients.
Limitations
Individual patient data from three trials were not obtained, and there was potential heterogeneity among trials due to different inclusion criteria.
Participant Demographics
{"age":{"median":61,"range":"52-70"},"sex_distribution":{"male":"76.4%","female":"23.6%"},"hypertension":"42.1%","diabetes":"14.6%","previous_MI":"8.0%","smoking":"52.4%"}
Statistical Information
P-Value
p<0.001
Confidence Interval
{"TIMI_flow":"95% CI 1.50 to 2.48","ST_segment_resolution":"95% CI 1.04 to 1.62"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website